Title : Tailored cellular environments to enable drug design
Abstract:
Over the past 50 years, drug delivery has evolved from localized injection to basic pharmacokinetic optimization to targeted intracellular delivery of therapeutics. While these advancements have been critical for supporting therapeutic efficacy and minimizing off-target effects, focusing on delivery alone is not enough. Success depends not only on directing the drug to the correct location but also on ensuring that cells can use the drug effectively.
There are well-established precedents for engineering the biological states of cells. For instance, vaccine adjuvants alter immune responses, while bioprocess engineers adjust factors like oxygen, pH, nutrients, osmolality, temperature, and metabolic burden to enhance cellular competency. In manufacturing, such conditioning boosts cells’ ability to produce complex biologics under stress. In therapeutic contexts, conditioning can heighten their capacity to interpret and implement delivered instructions. Delivery is only truly successful if the receiving biology is able to respond.
New Approach Methodologies (NAMs; organoids, organ-on-chip systems, iPSC models, continuous sensors, and computational platforms) mark the next architectural shift in drug development. By deconstructing the organism into defined components, NAMs increase mechanistic resolution but remove physiological context. Each model has its own maturation trajectory, metabolic conditions, stress history, and adaptive capacity. The challenge, therefore, is not only to measure biology but also to specify and stabilize the biological operating state in which those measurements occur.
Cellular state manipulation is the missing layer needed to optimize these processes. Notably, artificial intelligence (AI) tools can build meaningful biological databases only if biological responses are generated under defined, reproducible operating conditions. Without state control, AI trained on inconsistent, noisy, and biologically unstable data will be limited in utility.
To this end, we developed ETAERION, a unique, non-magnetic, non-crystalline iron-oxide nanoparticle designed for targeted manipulation of the cellular environment. Multifunctional biological conditioning technologies such as ETAERION represent a conceptual shift that can bolster drug development efforts. ETAERION are not strictly delivery vehicles; they are abiotic tools capable of conditioning the biological operating state, with or without delivering therapeutic cargo.
Vaccine adjuvants, bioprocess engineering, drug delivery, and NAMs all share a common principle: biology needs to be set in the correct operational state to respond reliably. The future of biotech lies not only in refining instructions or delivery techniques but also on enabling biology to respond effectively and training AI to interpret these responses. Tools like ETAERION help us move toward realizing this vision.
